A Phase I Study Using Most Closely HLA-matched BK Virus-specific T Lymphocytes for the Treatment of BK Virus Infections Post-allogeneic Stem Cell Transplant(VIRALYM-B)
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 12 Apr 2018
At a glance
- Drugs Polyomavirus specific T cells ViraCyte (Primary)
- Indications Human polyomavirus infections
- Focus Adverse reactions
- Acronyms VIRALYM-B
- Sponsors ViraCyte
- 09 Apr 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 22 Jan 2018 Planned initiation date changed from 1 Jan 2018 to 1 Mar 2018.
- 01 Nov 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.